First-line Axitinib plus Pembrolizumab in advanced renal cell carcinoma: retrospective real world data from a multicentre patient cohort

被引：0
|
作者：
Darr, Christopher [1 ,2 ]
Stelmach, Ramona [3 ]
Schlack, Katrin [4 ]
Dinkel, Hendrik [4 ]
Paffenholz, Pia [5 ,6 ]
Ivanyi, Philipp [7 ]
Wiegmann, Jonas [7 ]
Schulz, Anton
Kramer, Mario
Schnabel, Marco [8 ]
Rinderknecht, Emily [8 ]
Handke, Analena [9 ]
Hilser, Thomas
Heidenreich, Axel
Hadaschik, Boris [1 ,2 ,5 ,6 ]
Zschaebitz, Stefanie [3 ]
Gruenwald, Viktor [1 ,2 ,10 ]
机构：
[1] Univ Hosp Essen & German Canc Consortium DKTK, Dept Urol, Essen, Germany
[2] German Canc Consortium DKTK, Essen, Germany
[3] Heidelberg Univ Hosp, Dept Med Oncol, Natl Ctr Tumor Dis, Heidelberg, Germany
[4] Univ Hosp Muenster, Dept Urol, Munster, Germany
[5] Univ Cologne, Fac Med, Dept Urol Urooncol, Robot Assisted & Reconstruct Urol Surg, Cologne, Germany
[6] Univ Hosp Cologne, Cologne, Germany
[7] Dept Hematol Hemostasis Oncol & Stem Cell, Lubeck, Germany
[8] Univ Hosp Regensburg, Dept Urol, Regensburg, Germany
[9] Ruhr Univ Bochum, Marienhospital Herne, Dept Urol, Herne, Germany
[10] Univ Hosp Essen, Dept Oncol, Essen, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2024年 / 47卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
55
引用
收藏
页码：79 / 80
页数：2
相关论文
共 50 条
  • [1] Real-World Therapy Management and Outcomes of First-Line Axitinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma in the United States
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordon
    Levin, Rebecca
    Vlahiotis, Anna
    Rao, Dharanija
    Zanotti, Giovanni
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [2] Real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States.
    Zakharia, Yousef
    Thomaidou, Despina
    Li, Benjamin
    Siu, Gordan
    Levin, Rebecca
    Vlahiotis, Anna
    Zanotti, Giovanni
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [3] Cost-effectiveness of pembrolizumab plus axitinib as first-line therapy for advanced renal cell carcinoma
    Zhu, Jiaxin
    Zhang, Tiantian
    Wan, Ning
    Liang, Zhuoru
    Li, Jiahao
    Chen, Xudong
    Liang, Wenhua
    Jiang, Jie
    IMMUNOTHERAPY, 2020, 12 (17) : 1237 - 1246
  • [4] Real-world treatment modification of first-line axitinib plus pembrolizumab in patients with metastatic renal cell carcinoma (mRCC)
    Zakharia, Y.
    Thomaidou, D.
    Li, B.
    Siu, G.
    Levin, R.
    Vlahiotis, A.
    Zanotti, G.
    ANNALS OF ONCOLOGY, 2021, 32 : S1423 - S1424
  • [5] Updated analysis of real-world treatment outcomes of first-line axitinib plus pembrolizumab in patients with advanced renal cell carcinoma in the United States
    Zakharia, Yousef
    Vlahiotis, Anna
    Siu, Gordon
    Rao, Dharanija
    Teresi, Rosemary
    Eccleston, Anthony
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [6] Lenvatinib plus Pembrolizumab as first-line treatment in patients with advanced renal cell carcinoma (aRCC) - real world data from a retrospective multi- center analysis
    Stelmach, Ramona
    Schlack, Katrin
    Muhle, Clemens
    Darr, Christopher
    Neuberger, Stephanie
    Reichert, Mathias
    Rehlinghaus, Marc
    Flegar, Luka
    Zengerling, Friedemann
    Casuscelli, Jozefina
    Cox, Alexander
    Nestler, Tim
    Egenolf, Timo
    Brehmer, Bernhard
    Vallet, Sonia
    Ivanyi, Philipp
    Neuberger, Manuel
    Paffenholz, Pia
    Grunwald, Viktor
    Zschabitz, Stefanie
    ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 88 - 88
  • [7] Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan
    Harada, Ken-ichi
    Sato, Ryo
    Bando, Yukari
    Sano, Asuka
    Matsushita, Yuto
    Tamura, Keita
    Terakawa, Tomoaki
    Furukawa, Junya
    Fujimoto, Naohiro
    Fujisawa, Masato
    Miyake, Hideaki
    INTERNATIONAL JOURNAL OF UROLOGY, 2023, 30 (09) : 772 - 777
  • [8] HEALTH STATE UTILITIES IN PATIENTS WITH ADVANCED RENAL CELL CARCINOMA RECEIVING FIRST-LINE PEMBROLIZUMAB PLUS AXITINIB OR SUNITINIB
    Bensimon, A.
    Lai, Y.
    Xu, R.
    Bhattacharya, R.
    Shinde, R.
    VALUE IN HEALTH, 2022, 25 (07) : S554 - S554
  • [9] Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma
    Bensimon, Arielle G.
    Zhong, Yichen
    Swami, Umang
    Briggs, Allison
    Young, Joshua
    Feng, Yuan
    Song, Yan
    Signorovitch, James
    Adejoro, Oluwakayode
    Chakravarty, Abhiroop
    Chen, Mei
    Perini, Rodolfo F.
    Geynisman, Daniel M.
    CURRENT MEDICAL RESEARCH AND OPINION, 2020, 36 (09) : 1507 - 1517
  • [10] A COST-EFFCTIVENESS ANALYSIS OF PEMBROLIZUMAB PLUS AXITINIB VERSUS SUNITINIB FOR FIRST-LINE TREATMENT OF ADVANCED RENAL CELL CARCINOMA
    Gu, J.
    VALUE IN HEALTH, 2020, 23 : S32 - S32
12345